On Friday, the CNBC Investing Club held its February Monthly Meeting, where Jim Cramer and Director of Portfolio Analysis ran through each stock in the portfolio. Jim put a special focus on the Club stocks within the artificial intelligence trade. He’s dubbed them the “Fourth Industrial Revolution stocks,” borrowing the term from Nvidia CEO Jensen…
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have…
Novo Nordisk stock fell 13% Monday after it said its next-generation weight loss drug didn’t meet its key goal of showing that it wasn’t inferior to Eli Lilly’s rival drug. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks,…
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the White House, Nov. 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one — but recent weeks have delivered more…
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty Images CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant’s turnaround plan. “’24 was a tough year for…
A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine’s abilities and benefits to…
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. Tom Little | Reuters Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in…
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market. Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration had threatened legal action against Hims & Hers, which announced over the weekend it would not sell the pill. “Since launching the compounded…
Piotr Swat | Lightrocket | Getty Images Hims & Hers on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and threats of legal action earlier this week. “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” the telehealth…
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive…
